KRAS and colorectal carcinoma: Combinative treatment of β-elemene and cetuximab could induce ferroptosis of KRAS-mutant colorectal cancer cells (CRC) by iron-dependent ROS accumulation, GSH depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1), thus inhibiting tumor growth and lymph node metastases in vivo (Chen et al., 2020b).